TSC2 loss in neural progenitor cells suppresses translation of ASD/NDD-associated transcripts in an mTORC1- and MNK1/2-reversible fashion
Pauline Martin, Krzysztof J. SzkopiD, Francis Robert, Srirupa BhattacharyyaiD, Roberta L. Beauchamp, Jacob Brenner, Nicholas E. Redmond, Sidong HuangiD, Serkan ErdiniD, Ola Segnestam LarssoniD, Vijaya RameshiD
Abstract
Tuberous sclerosis complex (TSC) is an inherited neurodevelopmental disorder (NDD) with frequent manifestations of epilepsy and autism spectrum disorder (ASD). TSC is caused by inactivating mutations in TSC1 or TSC2 tumor suppressor genes, with encoded proteins hamartin (TSC1) and tuberin (TSC2) forming a functional complex inhibiting mechanistic target of rapamycin complex 1 (mTORC1) signaling. This has led to treatment with allosteric mTORC1 inhibitor rapamycin analogs ("rapalogs") for TSC tumors; however, rapalogs are ineffective for treating neurodevelopmental manifestations. mTORC1 signaling controls protein synthesis by regulating formation of the eIF4F complex, with further modulation by MNK1/2 kinases via phosphorylation of the eIF4F subunit eIF4E. While both these pathways modulate translation, comparing their impact on transcriptome-wide mRNA translation, as well as effects of inhibiting these pathways in TSC has not been explored. Here, employing CRISPR-modified, isogenic TSC2 patient-derived neural progenitor cells (NPCs), we have examined transcriptome-wide changes in mRNA translation upon TSC2 loss. Our results reveal dysregulated translation in TSC2-Null NPCs, which significantly overlaps with the translatome from TSC1-Null NPCs. Interestingly, numerous non-monogenic ASD-, NDD-and epilepsy-associated genes identified in patients harboring putative loss-of-function mutations, were translationally suppressed in TSC2-Null NPCs. Importantly, translation of these ASD- and NDD-associated genes was reversed upon inhibition of either mTORC1 or MNK1/2 signaling using RMC-6272 or eFT-508, respectively. This study establishes the importance of mTORC1-eIF4F- and MNK-eIF4E-sensitive mRNA translation in TSC, ASD and other neurodevelopmental disorders laying the groundwork for evaluating drugs in clinical development that target these pathways as a treatment strategy for these disorders.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Raptor downregulation rescues neuronal phenotypes in mouse models of Tuberous Sclerosis Complex
Vasiliki Karalis, Franklin S. Caval-Holme, Helen S. Bateup·Nature CommunicationsPeer-reviewed·Aug 9, 2022
- Loss of Tsc1 in cerebellar Purkinje cells induces transcriptional and translation changes in FMRP target transcripts
Jasbir Singh Dalal, Kellen Diamond Winden, … Mustafa Şahin·eLifePeer-reviewed·Jul 14, 2021
- A Bitopic mTORC Inhibitor Reverses Neural Phenotypes in a Tuberous Sclerosis Complex Murine Model of SEGA-like Hamartomas
Sulagna Mukherjee, Matthew J Wolan, … David M. Feliciano·Scientific ReportsPeer-reviewed·Jul 1, 2025
- The phosphoproteomic landscape of the neurological manifestations in tuberous sclerosis complex
Marie Girodengo, Simeon R. Mihaylov, … Joseph M. Bateman·Acta NeuropathologicaPeer-reviewed·May 20, 2026
- Tsc1 haploinsufficiency leads to Pax2 dysregulation in the developing murine cerebellum
Ines Serra, Ana Stravs, … Aleksandra Badura·Frontiers in Molecular NeurosciencePeer-reviewed·May 13, 2022
- Human TSC2 Mutant Cells Exhibit Aberrations in Early Neurodevelopment Accompanied by Changes in the DNA Methylome
Mary‐Bronwen L. Chalkley, Lindsey N. Guerin, … Rebecca A. Ihrie·Human Molecular GeneticsPeer-reviewed·Jan 22, 2025